Strategic Cooperation
Elem Biotech provides customers with high-throughput gene editing products and services, focusing on deep and long-term strategic cooperation with customers;
Empower Chinese pharmaceutical companies and Chinese researchers to provide high-level and accessible solutions for innovative drug research and development and basic research!
Protein Degradation Drug Development
The Bio-Bio team is deeply engaged in the field of protein degradation drug development, providing services from target discovery and confirmation, lead compound discovery and optimization, drug mechanism (MOA) research, PK/PD and other links;
Elem Biotech provides high-throughput gene editing products (KO/KI cell lines) and supporting mass spectrometry detection services to optimize and accelerate the above research process.
Large Molecule/Small Molecule Drug Development
The Elem team promotes the construction of reporter cell lines for hot pharmaceutical targets, the construction of point mutation cell lines for drug resistance screening, and the construction of in situ gene insertion and over-expression cell lines;
Elem high-throughput gene knock-in platform, which can screen out drug target stable reporter cell lines within 2 weeks, and Elem currently accumulates 150 popular pharmaceutical target stable reporter cell lines, which are continuing to increase.
Deep Proteomics Technology
Based on deep proteomics technology, Elem completes the accumulation of group data of 300 tumor cell lines and accumulates a large amount of data support for high-throughput gene knockout/knock-in platform;
Elem's high-throughput gene knockout platform uses "proteomics Sanger sequencing" to jointly evaluate gene knockout efficiency at the gene and protein levels to establish high-quality industry standards for KO products.
Copyright © Elem Biotechnology (Wuhan) Co., Ltd.
LM